Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Most patients notice side effects after starting medication for the first time or immediately after a dose increase
Figures Abstract Background Incretinbased therapies which include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are recommended by several practice guidelines as second-line agents for add-on therapy to metformin in patients with type 2 diabetes (T2DM) who do not achieve glycemic control with metformin plus lifestyle interventions alone
You may have to try alternative, lower-cost medications to treat your medical conditions before moving to a more expensive drug like Zepbound
With the exception of Harvoni, Mounjaro and Zepbound are the only launch products ever to surpass $5 billion in sales in their first 12 months and their sales have only continued to grow
US$ 25.21
US$ 20.86
US$ 29.80
US$ 26.16
US$ 21.19
